Akili, Inc.
akiliinteractive.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 14, 2024. Its latest SEC filing is a SC 13G/A from Nov 13, 2024.
10-Q for Q1 FY2024, filed May 14, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells video game-based digital treatments designed to improve attention for people with ADHD, including children and adults.
10-K for FY2023, filed Feb 29, 2024With this approach, we introduced EndeavorRx®, the first prescription video game treatment (and first digital treatment for a cognitive…View ↗
In June 2023, we released EndeavorOTC®, which is built on the same platform as EndeavorRx, nationwide as an over-the-counter product that…View ↗
Our platform is powered by proprietary therapeutic engines, which are software and associated algorithms that form the core of our products…View ↗
How Did They Make Money?
Caregivers and patients pay in advance for EndeavorRx subscriptions, with payments earned across the subscription term; EndeavorOTC customers pay in advance for one-month or one-year subscriptions, earned when access is delivered. Akili also earns revenue under a collaboration agreement with Shionogi.
10-K for FY2023, filed Feb 29, 2024The Company generates revenue from contracts with caregivers and patients who purchase subscriptions to access EndeavorRx (“Clients”), the…View ↗
F-11 same method and pattern of recognition. Accordingly, the consideration is recognized ratably on an over time basis over the…View ↗
In June 2023, the Company released its EndeavorOTC over-the-counter product under the FDA’s COVID-19 Guidance. The Company generates…View ↗
The Company has generated revenue from a collaboration agreement with Shionogi. The consideration allocated to each performance obligation…View ↗
$1.7M
-
10-K for FY2023, filed Feb 29, 2024
$1.7M ↗
Who Were Their Customers?
Caregivers and patients buy EndeavorRx subscriptions, while adults with ADHD buy EndeavorOTC subscriptions.
10-K for FY2023, filed Feb 29, 2024
Did Revenues Turn Into Profits?
No. It lost $59.5M in FY2023.
10-K for FY2023, filed Feb 29, 2024
−$64.5MView ↗
10-K for FY2023, filed Feb 29, 2024
−$59.5MView ↗
10-K for FY2023, filed Feb 29, 2024
−$57.9MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 14, 2024
−$9.8MView ↗
- ▼ −53% (Loss)
- vs −$20.7M in Q1 FY2023
-
Jul 2, 2024
Akili became a wholly owned subsidiary of Virtual Therapeutics
Sources
8-K, filed Jul 2, 2024
As previously disclosed by Akili, Inc. (the “Company” or “Akili”) in the Company’s Current Report on Form 8-K filed with the Securities and…View ↗
Loading...
